SignalXSignalX

Fulgent Genetics, Inc. (FLGT) 8-K Current Report: March 17, 2026

Filed: March 17, 2026
Health Care
Services-Medical Laboratories
Fulgent Genetics, Inc. Overview

Fulgent Genetics, Inc. (FLGT) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 2.01: Completion of Acquisition or Disposition of Assets
  • Item 7.01: Regulation FD Disclosure

Fulgent Genetics, Inc. 8-K Mar 17, 2026 Event Analysis

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • • Combined cash consideration ~$56.9M ($13.5M for StrataDx equity + $43.4M for Bako assets), both deals closed March 17, 2026
  • • APA covers dermatopathology, podiatric pathology, molecular diagnostics, and therapeutic products — direct bolt-on to Inform Diagnostics subsidiary
  • • Lease assumed for 29,099 sq ft lab/office in Alpharetta, GA at $15.54/sq ft annually (~$452K/yr base rent), running through July 2026 with 2% annual escalator
  • • Both purchase prices subject to post-closing adjustments; escrow accounts funded at closing to secure potential true-ups
  • • Acquisitions expand FLGT's diagnostics footprint in dermatopathology — a specialty segment with recurring lab volume and potential cross-sell into Fulgent's genomics platform

Item 7.01 · Regulation FD Disclosure

  • • Fulgent Genetics (FLGT) and Consonance Capital Partners announced dual transaction closings: PSA (Purchase and Sale Agreement) and APA (Asset Purchase Agreement)
  • • Joint closing signals completion of a significant asset transaction with Consonance, a healthcare-focused investment firm
  • • Press release dated March 17, 2026 attached as Exhibit 99.1 — full deal terms and financial details contained there

Other Fulgent Genetics, Inc. 8-K Filings

8-K Feb 27, 2026

Get deeper insights on Fulgent Genetics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.